Abstract
Glycogen synthase kinase‐3β (GSK‐3β) is a multifunctional serine‐threonine kinase, which is expressesed in all eukaryotic cells. Many diseases, such as metabolic diseases, cancer, digestive diseases and lung diseases, have been confirmed to be associated with the changes of expression level of GSK‐3β. At present, studies have found that it is also involved in the development of nervous system diseases such as traumatic brain injury, Alzheimer's psychosis, etc. This article summarizes the regulatory mechanism of GSK‐3β in the development of nerve diseases and intends to clarify the mechanisms of nervous system disease to guide its application in future clinic trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
